1. Home
  2. ZNTL vs IPHA Comparison

ZNTL vs IPHA Comparison

Compare ZNTL & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

N/A

Current Price

$1.37

Market Cap

165.1M

Sector

Health Care

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$0.94

Market Cap

167.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZNTL
IPHA
Founded
2014
1999
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.1M
167.6M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
ZNTL
IPHA
Price
$1.37
$0.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
3
Target Price
★ $7.44
$7.00
AVG Volume (30 Days)
★ 1.3M
25.1K
Earning Date
11-09-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.03
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$427.26
Revenue Next Year
N/A
$88.11
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.28
$1.06
52 Week High
$6.95
$2.71

Technical Indicators

Market Signals
Indicator
ZNTL
IPHA
Relative Strength Index (RSI) 22.22 23.73
Support Level N/A N/A
Resistance Level $1.98 $1.59
Average True Range (ATR) 0.18 0.08
MACD -0.01 -0.04
Stochastic Oscillator 0.72 1.86

Price Performance

Historical Comparison
ZNTL
IPHA

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: